aventis submits application for Menactra

[Guest guest]

" Aventis Submits Application to FDA for Menactra "

Dow Newswire (www.djnewswires.com) (12/22/03)

Aventis has filed a Biologics Licensing Application to U.S. officials for

marketing approval of its Menactra Meningococcal Polysaccharide Diphtheria

Toxoid Conjugate Vaccine.  The submission requests marketing approval of

the vaccine against meningococcal meningitis for adolescents and adults

between the ages of 11 and 55 years.  Next year, Aventis plans to request

approval of Menactra for individuals between the ages of two and 55 years

in Europe and for groups under the age of 11 in the United States.